[Chronic myeloid leukemia as a model for the development and therapeutic use of tyrosine kinase inhibitors].
López-Karpovitch
Xavier
X
xlopezk@quetzal.innsz.mx
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001549:Benzamides; D002986:Clinical Trials as Topic; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors* / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D015465:Leukemia, Myeloid, Accelerated Phase / Q000188:drug therapy / Q000628:therapy; D015337:Multicenter Studies as Topic; D009196:Myeloproliferative Disorders / Q000188:drug therapy / Q000201:enzymology; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000201:enzymology; D015514:Oncogene Proteins, Fusion / Q000037:antagonists & inhibitors; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D016879:Salvage Therapy; D016896:Treatment Outcome
D001549:Benzamides; D004791:Enzyme Inhibitors; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl